Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Mar 7;107(3):487–498. doi: 10.1016/j.ijrobp.2020.02.031

Fig. 2.

Fig. 2.

MEDI0457 and chemoradiation is associated with humoral immune responses against HPV16 or HPV17 E6/E7 antigens in the majority of patients with cervical cancer treated with chemoradiation. (A) Antibody responses against HPV16 E6 antigen (far left panel), HPV18 E6 antigen (center left panel), HPV16 E7 antigen (center right panel), and HPV18 E7 antigen (far left panel) in patients treated for newly diagnosed, locally advanced cervical cancer (cohort 1). (B) Antibody responses against HPV16 or HPV18 E6/E7 antigen in patients treated for recurrent or persistent cervical cancer (cohort 2). Antibody titers were measured using ELISA assays. Abbreviations: ELISA = enzyme-linked immunosorbent assay; HPV = human papilloma virus.